Tehran University of Medical Sciences Journal of Pharmaceutical Care 2322-4630 10 3 2022 10 01 183 187 Amir ali Ghahremani Department of Neurology, North Khorasan University of Medical Sciences, Bojnord, Iran Amir Bigdeli Department of Nephrology, North Khorasan University of Medical Sciences, Bojnord, Iran Davoud Salarbashi Nanomedicine Research Center, School of Medicine, Gonabad University of Medical Sciences , Gonabad, Iran AND Department of Nutrition and Food Sciences, School of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran Pouyan Shakouri Student Research Committee, School of Medicine, North Khorasan University of Medical Sciences, Bojnord, Iran. Sepideh Elyasi Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. 2022 06 28 2022 08 20 Neurologic complications in patients with coronavirus disease 19 (COVID-19) are common particularly in hospitalized patients. Guillain–Barré syndrome (GBS) is a rare complication of COVID-19. Most patients with GBS and COVID-19 presented with progressive, ascending limb weakness evolving over one to four days. There are some reported cases of GBS, mostly in form of case reports or case series, and also a comprehensive review on this topic. However, none of these cases experienced multiple sclerosis (MS) as an underlying disease. So, in this manuscript we reported three cases of COVID-19 induced GBS; one of them with history of MS and promising outcome after receiving five session of plasmaphresis and corticosteroid therapy. https://jpc.tums.ac.ir/index.php/jpc/article/view/508